tiprankstipranks
Trending News
More News >
Livzon Pharmaceutical Group Class H (HK:1513)
:1513
Hong Kong Market

Livzon Pharmaceutical Group (1513) Income Statement

Compare
1 Followers

Livzon Pharmaceutical Group Income Statement

Last quarter (Q2 2025), Livzon Pharmaceutical Group's total revenue was ¥3.09B, an increase of 1.71% from the same quarter last year. In Q2, Livzon Pharmaceutical Group's net income was ¥644.38M. See Livzon Pharmaceutical Group’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
¥ 11.81B¥ 12.43B¥ 12.63B¥ 12.06B¥ 10.52B
Gross Profit
¥ 7.73B¥ 7.66B¥ 8.17B¥ 7.81B¥ 6.85B
Operating Expenses
¥ 4.89B¥ 5.24B¥ 5.93B¥ 5.62B¥ 4.53B
Depreciation and Amortization
¥ 575.14M¥ 840.32M¥ 652.32M¥ 445.27M¥ 394.30M
EBITDA
¥ 3.47B¥ 3.33B¥ 3.08B¥ 2.77B¥ 2.91B
Operating Income
¥ 2.84B¥ 2.42B¥ 2.35B¥ 2.27B¥ 2.50B
Other Income/Expenses
¥ -38.25M¥ -32.44M¥ -20.01M¥ -21.30M¥ -11.01M
Pretax Income
¥ 2.81B¥ 2.38B¥ 2.33B¥ 2.25B¥ 2.49B
Net Income
¥ 2.06B¥ 1.95B¥ 1.91B¥ 1.78B¥ 1.71B
Per Share Metrics
Basic EPS
¥ 2.24¥ 2.10¥ 2.04¥ 1.90¥ 1.83
Diluted EPS
¥ 2.24¥ 2.10¥ 2.04¥ 1.90¥ 1.83
Weighted Average Shares Outstanding
920.13M 930.31M 933.86M 934.46M 936.16M
Weighted Average Shares Outstanding (Diluted)
920.13M 930.61M 935.98M 934.57M 937.11M
Currency in CNY

Livzon Pharmaceutical Group Earnings and Revenue History